The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy (Q35073349)

6 August 2017

1 reference

title

The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy (English)

1 reference

6 August 2017

main subject

anti-retroviral agent

0 references

author name string

Stephen L Becker

series ordinal

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

401-412

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Human alpha-1-glycoprotein and its interactions with drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Interactions among drugs for HIV and opportunistic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.401

10.1517/13543784.12.3.401

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference